In my August 23 Zoom Video Communications (ZM) post, I disclosed my rationale for initiating a position in this company. Part of my analysis included a review of ZM's proxy. On Page 16, I noted that one of the continuing Directors (Peter Gassner) is the CEO and a member of the board of directors of [...]
Even if we invest in a great company, not every investment decision we make ends up being a wise one. We should, however, at least give ourselves a fighting chance of generating a decent investment return. Case in point? Nike (NKE). Pay attention to Nike's valuation otherwise you risk disappointment. NKE is a great company [...]
Paychex (PAYX) should appeal to risk-averse investors given its strong recurring revenue, and operating and free cash flow. I last reviewed it in this September 28 post at which time it had just released Q1 2024 results and raised its FY2024 outlook for the adjusted diluted EPS and Interest on Funds Held for Clients metrics. [...]
In my September 15, 2019 HEICO Corporation (HEI and HEI-a) post, I disclosed the purchase of 300 shares @ ~$99/share in one of the 'Side' accounts in the FFJ Portfolio. Subsequently, I have increased my exposure to 400 shares in a 'Core' account and 400 shares in a 'Side' account. What initially peaked my interest [...]
Income seeking investors who prioritize dividend metrics in their investment decision making process should consider CME Group (CME) as a potential investment. While it has consistently increased its dividend payout for 13 consecutive years, the real 'kicker' is the variable component. CME's dividend policy targets a regular quarterly dividend of between 50% - 60% of [...]
In my December 8 guest post at Dividend Power, I outline how Thermo Fisher Scientific consistently creates shareholder value and why I think this is an opportune time to acquire shares despite its valuation is not as attractive as in late October/early November. Thermo Fisher's share price can be volatile. Just before Christmas 2021, for [...]
In late October/early November, identifying attractively valued wonderful companies was reasonably easy. Irrational exuberance, however, returned part way through November. This has me thinking that many investors are making emotional investment decisions. This is a terrible way to invest since our emotions have a tremendous influence over our expectations. When we neglect to look at [...]
The phrase 'exit stage right' is a playwright's way of giving clear directions for a character to leave the stage. This is exactly what I have done with my Abbvie (ABBV) exposure. In my December 2 Why I Am Not Increasing My AbbVie Exposure post, I explain my decision not to add to my ABBV [...]
Alimentation Couche-Tard (ATD.to) is arguably the best operator in the highly fragmented convenience store industry. Despite being a wonderful company, however, shares are currently fairly valued. I am not, therefore, currently adding to my exposure. I think we are once again experiencing a period of irrational exuberance. In late October/early November, it was easy to [...]
I last reviewed Abbvie (ABBV) in my November 12, 2022 post at which time I expressed my relief that ABBV was deleveraging. Now, however, ABBV's debt will increase because of its recently announced ImmunoGen (IMGN) acquisition. I am, therefore, not increasing my Abbvie exposure for reasons presented herein. In my previous post, I also commented [...]